About MSD Pharmaceuticals Private Limited
Data last updated:
MSD Pharmaceuticals Private Limited is a private limited company based in New Delhi, Delhi, India, a subsidiary of Merck Sharp & Dohme B.V.. It operates in the pharmaceutical retail and distribution segment of the pharmaceuticals sector. It was incorporated on 03 December 2004 and has been in existence for over 22 years.
The company is registered with the Registrar of Companies (ROC), Delhi, under CIN U24230DL2004PTC164459. Its GSTIN is 07AAECM1106C1Z7 (Delhi). The company holds 18 GST registrations, of which 11 are active.
The company has an authorised share capital of ₹15 Cr and a paid-up capital of ₹13.2 Cr. It is led by directors Rehan Khan Abbas (Managing Director) and Chand Berry (Whole-Time Director).
Its last annual general meeting (AGM) was held on 29 August 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at 1544 Level 15 Eros Corporate Towers Nehru Place, New Delhi, Delhi, India – 110019.
As per the financials filed for FY 2025, the company reported a revenue of ₹2,748.9 Cr, a growth of 35% compared to the previous year. For the same year it recorded a net profit of ₹352.63 Cr (net margin 12.8%) and EBITDA of ₹551.03 Cr (EBITDA margin 20%). Revenue has grown at a compounded annual rate (CAGR) of 21% over three years and 16% over five years.
The company has about 1,146 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Merck Sharp & Dohme. Court records list 18 cases involving the company, including 4 filed by the company and 11 filed against it; 4 cases are pending. The company has 1 deal on record (1 secondary share transfer); the latest was in June 2007. Its 10 peer companies in the Pharma industry (Pharma Retail and Distribution, Pharmaceuticals) are compared by revenue, 5 larger and 5 smaller; the largest is J B Chemicals and Pharmaceuticals Limited with revenue of ₹3,956.31 Cr. The company has 11 MSME Form 1 returns on record between 2019 and 2023, listing 391 overdue payments to 52 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website msdindia.in.
- EmailLocked
- TelephoneLocked
- Website
- Social Media
- Registered Address1544 Level 15 Eros Corporate Towers Nehru Place, New Delhi, Delhi, India – 110019
- IndustryPharma, Pharmaceutical Retailers & Distributors
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Business Activity of MSD Pharmaceuticals Private Limited
The main business activity of MSD Pharmaceuticals is trade. In detail, this covers retail trading.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| G | Trade | G2 | Retail Trading | Locked |
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of MSD Pharmaceuticals Private Limited FY 2025 filings available
MSD Pharmaceuticals Private Limited reported revenue of ₹2,748.9 Cr (up 35% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR) of MSD Pharmaceuticals Private Limited
Revenue has grown at a compounded annual rate (CAGR) of 16% over five years, including 35% growth in the latest year. EBITDA rose 6% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary of MSD Pharmaceuticals Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | •••• | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• | •••• |
| Total Revenue | •••• | •••• | •••• | •••• | •••• |
| Cost of Materials Consumed | •••• | •••• | •••• | •••• | •••• |
| Employee Benefit Expense | •••• | •••• | •••• | •••• | •••• |
| Finance Costs | •••• | •••• | •••• | •••• | •••• |
| Depreciation and Amortisation | •••• | •••• | •••• | •••• | •••• |
| Other Expenses | •••• | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• | •••• |
| EBITDA | ₹551.03 Cr | •••• | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• | •••• |
| Tax Expense | •••• | •••• | •••• | •••• | •••• |
| Net Profit (PAT) | ₹352.63 Cr | •••• | •••• | •••• | •••• |
| Balance Sheet | |||||
| Share Capital | •••• | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• | •••• |
| Net Worth (Total Equity) | •••• | •••• | •••• | •••• | •••• |
| Long-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Short-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• | •••• |
Financial Ratios of MSD Pharmaceuticals Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 20% | •••• | •••• | •••• | •••• |
| Net Profit Margin | 12.8% | •••• | •••• | •••• | •••• |
| Return on Equity (ROE) | •••• | •••• | •••• | •••• | •••• |
| Return on Capital Employed (ROCE) | •••• | •••• | •••• | •••• | •••• |
| Return on Assets (ROA) | •••• | •••• | •••• | •••• | •••• |
| Liquidity and Debt | |||||
| Current Ratio | •••• | •••• | •••• | •••• | •••• |
| Quick Ratio | •••• | •••• | •••• | •••• | •••• |
| Debt-to-Equity Ratio | •••• | •••• | •••• | •••• | •••• |
| Interest Coverage Ratio | •••• | •••• | •••• | •••• | •••• |
| Efficiency and Growth | |||||
| Asset Turnover | •••• | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• | •••• |
| Payable Days | •••• | •••• | •••• | •••• | •••• |
| Inventory Days | •••• | •••• | •••• | •••• | •••• |
| Revenue Growth | •••• | •••• | •••• | •••• | •••• |
| Net Profit Growth | •••• | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of MSD Pharmaceuticals are in the company report.
Financial statements from 2015
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Peer Comparison of MSD Pharmaceuticals Private Limited
MSD Pharmaceuticals Private Limited is compared with the companies closest to it by revenue in the Pharma industry (Pharma Retail and Distribution, Pharmaceuticals). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| J B Chemicals and Pharmaceuticals Limited Listed | ₹3,956.31 Cr (FY 2025) | •••• | •••• | 12.0% | •••• | Ahmedabad, Gujarat, India |
| Glaxosmithkline Pharmaceuticals Limited Listed | ₹3,895.14 Cr (FY 2025) | •••• | •••• | 9.0% | •••• | Mumbai, Maharashtra, India |
| Cadila Pharmaceuticals Limited | ₹3,869.17 Cr (FY 2025) | •••• | •••• | 4.0% | •••• | Ahmedabad, Gujarat, India |
| Novo Nordisk India Private Limited | ₹3,332.65 Cr (FY 2025) | •••• | •••• | 16.0% | •••• | Bangalore, Karnataka, India |
| Amneal Pharmaceuticals Private Limited | ₹2,944.87 Cr (FY 2025) | •••• | •••• | 6.0% | •••• | Ahmedabad, Gujarat, India |
| MSD Pharmaceuticals Private Limited this company | ₹2,748.9 Cr (FY 2025) | •••• | •••• | 35.0% | •••• | New Delhi, Delhi, India |
| Centrient Pharmaceuticals India Private Limited | ₹2,240.1 Cr (FY 2025) | •••• | •••• | 8.0% | •••• | Toansa, Punjab, India |
| Iol Chemicals and Pharmaceuticals Limited Listed | ₹2,101.62 Cr (FY 2025) | •••• | •••• | -3.0% | •••• | Barnala, Punjab, India |
| Dishman Pharmaceuticals and Chemicals Limited | ₹1,622.59 Cr (FY 2016) | •••• | •••• | -3.0% | •••• | Ahmedabad, Gujarat, India |
| Palepu Pharma Distributors Private Limited | ₹1,608.11 Cr (FY 2025) | •••• | •••• | 15.0% | •••• | Chennai, Tamil Nadu, India |
| Cipla Pharma and Life Sciences Limited | ₹1,598.45 Cr (FY 2025) | •••• | •••• | -2.0% | •••• | Mumbai, Maharashtra, India |
Peers are the five companies nearest above and the five nearest below MSD Pharmaceuticals by revenue in the Pharma industry (Pharma Retail and Distribution, Pharmaceuticals), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Auditor Details of MSD Pharmaceuticals Private Limited
MSD Pharmaceuticals Private Limited is audited by Lovelock & Lewes Chartered Accountants LLP for the financial year 2023.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| Lovelock & Lewes Chartered Accountants LLP | Locked | Locked | Locked |
Complete auditor history
Appointment and cessation dates and past auditor changes are in the company report.
- Appointment status
- Appointment dates
- Cessation dates
- Auditor changes
Verified entity values are shown only after access is granted.
Board of Directors of MSD Pharmaceuticals Private Limited
MSD Pharmaceuticals has 2 current directors and 17 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Chand Berry | Whole-Time Director | 30 Sep 2021 | 5 Years 0 Months | Current |
| Rehan Khan Abbas Also directs: Metropolis Healthcare Limited | Managing Director | 07 May 2021 | 5 Years 5 Months | Current |
Ownership and Shareholding of MSD Pharmaceuticals Private Limited
Shareholding and ownership data
Promoter, institutional, public and beneficial ownership figures are in the company report.
- Ownership categories
- Historical changes
- Group structure
- FII and DII holdings
Verified entity values are shown only after access is granted.
Charges & Borrowings of MSD Pharmaceuticals Private Limited
MSD Pharmaceuticals Private Limited does not have any charges (loans) registered with the Registrar of Companies.
Deals & Funding of MSD Pharmaceuticals Private Limited
MSD Pharmaceuticals Private Limited has 1 deal on record (1 secondary share transfer); the latest was in June 2007.
Deals on record (1 of 1)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Jun 2007 | Secondary share transfer | Undisclosed | Buyer: MSD Finance B V, Msd Human Health Holding B.v. (Msd Hhh B.v.) Seller: 2 individuals |
Full deal history
All 1 deals with amounts, valuations, instruments and every party are in the company report.
- Every funding round and share transfer
- Amounts and valuations
- Investors, buyers and sellers
- Instruments and deal dates
Verified entity values are shown only after access is granted.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal Cases of MSD Pharmaceuticals Private Limited
MSD Pharmaceuticals Private Limited has 18 court cases on record: 4 filed by MSD Pharmaceuticals, 11 filed against it, 3 where it is another party. 4 cases are pending and 14 are disposed. Status as checked between 21 Sep 2026 and 05 Oct 2026.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 10 | 5 | 3 |
| Supreme Court | 4 | 4 | 1 |
| District courts | 4 | 2 | 0 |
Cases on record (5 of 18)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Gangtok, Sikkim | Court case (Us 148 (a) (caveat)) | Filed against the company by Glenmark Generics Limited | Disposed |
| High Court of Delhi | Writ petition | Filed by the company against Principal Commissioner of Income Tax- 4, New Delhi & Ors | Pending |
| High Court of Karnataka | Writ petition | Company is another party | Pending |
| High Court of Chhattisgarh | Court case (WPL) | Company is another party | Pending |
| Supreme Court | Special leave petition | Filed against the company by PR. Commissioner of Income Tax 6 | Pending |
Full case history
All 18 cases with case numbers, court, year-wise trend, opposite parties and decision dates are in the company report.
- Every case with its case number
- Year-wise trend
- Opposite parties
- Decision dates and orders
Verified entity values are shown only after access is granted.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME Payment Delays by MSD Pharmaceuticals Private Limited
MSD Pharmaceuticals Private Limited has 11 MSME Form 1 returns on record between 2019 and 2023, listing 391 overdue payments to 52 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 52)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| an individual supplier | •••• | •••• | •••• |
| FCC Logistics Private Limited | •••• | •••• | •••• |
| an individual supplier | •••• | •••• | •••• |
| an individual supplier | •••• | •••• | •••• |
| Ambetronics Engineers Private Limited | •••• | •••• | •••• |
Full MSME payment history
Every supplier, amount and due date from all 11 MSME Form 1 returns is in the company report.
- Every reported supplier due
- Amounts and due dates
- Reasons given in each return
- Period-by-period history
Verified entity values are shown only after access is granted.
Individuals and sole proprietors among the suppliers are not named. Amounts, due dates and filing dates are in the company report.
Associated Brands with MSD Pharmaceuticals Private Limited
MSD Pharmaceuticals operates one associated brand: Merck Sharp & Dohme. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Therapies for HIV, cancer, diabetes, and infectious diseases are developed. | msd.com |
Employees and EPFO Compliance at MSD Pharmaceuticals Private Limited
MSD Pharmaceuticals Private Limited has a workforce of 1,146 employees as of Mar 31, 2024.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
CIN History of MSD Pharmaceuticals Private Limited
MSD Pharmaceuticals has one previous CIN (Corporate Identification Number): U24230MH2004PTC149814. The current CIN is U24230DL2004PTC164459, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24230DL2004PTC164459 | Current |
| U24230MH2004PTC149814 | Previous |
News related to MSD Pharmaceuticals Private Limited
Recent Activity on MSD Pharmaceuticals Private Limited
MSD Pharmaceuticals Private Limited has 34 board changes on record since 2004: 18 appointments and 16 cessations. The latest: Yashodhara Dilip Ghorpade ceased to be Whole-Time Director on 10 Oct 2025.
25 earlier events are listed in the company report.
Credit Ratings, Litigation & Regulatory Alerts for MSD Pharmaceuticals Private Limited
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of MSD Pharmaceuticals Private Limited
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of MSD Pharmaceuticals Private Limited
MSD Pharmaceuticals has 18 GST registrations: 11 active and 7 cancelled or inactive. The first 4 active GSTINs are listed below.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 07AAECM1106C1Z7 | Delhi | Active | 01 Jul 2017 |
| 06AAECM1106C1Z9 | Haryana | Active | 01 Jul 2017 |
| 08AAECM1106C1Z5 | Rajasthan | Active | 01 Jul 2017 |
| 19AAECM1106C1Z2 | West Bengal | Active | 01 Jul 2017 |
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of MSD Pharmaceuticals Private Limited
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about MSD Pharmaceuticals Private Limited
MSD Pharmaceuticals is an active private limited company based in New Delhi, Delhi, India. The company works in pharmaceutical retailers and distributors, within the pharma industry. It was incorporated on 03 December 2004 (22+ years old) and is registered under CIN U24230DL2004PTC164459.
MSD Pharmaceuticals reported revenue of ₹2,748.9 Cr for FY 2025 (up 35% YoY).
MSD Pharmaceuticals has 2 current directors:
- Rehan Khan Abbas - Managing Director
- Chand Berry - Whole-Time Director
MSD Pharmaceuticals reported a net profit of ₹352.63 Cr (net margin 12.8%) and EBITDA of ₹551.03 Cr (EBITDA margin 20%) for FY 2025, as per its filed financial statements.
The compounded annual growth rate (CAGR) of the revenue of MSD Pharmaceuticals is 21% over three years and 16% over five years. In the latest year (FY 2025) revenue rose 35%. CAGR is the steady yearly rate that links the first and the last year.
The GSTIN of MSD Pharmaceuticals is 07AAECM1106C1Z7, registered in Delhi. The company has 18 GST registrations in all, of which 11 are active and 7 are cancelled or inactive. Other active GSTINs include 06AAECM1106C1Z9 (Haryana), 08AAECM1106C1Z5 (Rajasthan), 19AAECM1106C1Z2 (West Bengal).
The CIN (Corporate Identification Number) of MSD Pharmaceuticals is U24230DL2004PTC164459. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
MSD Pharmaceuticals has 18 court cases on record: 4 filed by the company and 11 filed against it. 4 are pending. Most are in the high courts.
MSD Pharmaceuticals was incorporated on 03 December 2004, making it 22+ years old. It is registered with the Registrar of Companies, Delhi.
MSD Pharmaceuticals has 1 deal on record (1 secondary share transfer); the latest was in June 2007.
The peers of MSD Pharmaceuticals by revenue are J B Chemicals and Pharmaceuticals Limited, Glaxosmithkline Pharmaceuticals Limited, Cadila Pharmaceuticals Limited, Novo Nordisk India Private Limited, Amneal Pharmaceuticals Private Limited and 5 more, all in the Pharma industry (Pharma Retail and Distribution, Pharmaceuticals).
Yashodhara Dilip Ghorpade ceased to be Whole-Time Director on 10 Oct 2025. Yashodhara Dilip Ghorpade was appointed as Whole-Time Director on 06 Sep 2023. Muralidhar Venkata Karanam ceased to be Whole-Time Director on 24 Aug 2023. MSD Pharmaceuticals has 34 board changes on record in total.